Servier adds oncology growth driver via $2.5B Day One buyout

Coming off a year in which a brain cancer drug emerged as its biggest growth driver, Servier is adding an approved pediatric glioma therapy to its portfolio through its $2.5 billion acquisition of Day One.

The deal will give the French pharma U.S. rights to Ojemda tovorafenib, which has accelerated approval to treat pediatric low-grade glioma (pLGG) in patients with a BRAF fusion or rearrangement, or a BRAF V600 mutation. Ipsen holds ex-U.S. rights to the oral, selective RAF kinase inhibitor under a July 2024 deal...